RWM
ESPR icon

Rialto Wealth Management’s Esperion Therapeutics ESPR Stock Holding History

Rialto Wealth Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87K Hold
593
– – ﹤0.01% 1136
2026
Q1 		$1.63K Hold
593
– – ﹤0.01% 941
2025
Q4 		$2.19K Hold
593
– – ﹤0.01% 718
2025
Q3 		$1.57K Hold
593
– – ﹤0.01% 745
2025
Q2 		$584 Buy
593
+297
+100% +$297 ﹤0.01% 1063
2025
Q1 		$427 Buy
+296
New +$545 ﹤0.01% 964

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Rialto Wealth Management's ESPR Position: Q2 2026 in Review

Rialto Wealth Management held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 593 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #1136.

Rialto Wealth Management first reported a position in ESPR in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.19K in Q4 2025. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Rialto Wealth Management held 593 shares of Esperion Therapeutics worth $1.87K as of Q2 2026.
  • Rialto Wealth Management left its Esperion Therapeutics share count unchanged in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1136 holding.
  • Rialto Wealth Management first reported a position in Esperion Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Rialto Wealth Management's Esperion Therapeutics position peaked at $2.19K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.